$CLMT

Sajkowski Daniel J sold $153K of CLMT

Sajkowski Daniel J sold 4,240 shares of Calumet, Inc. /DE (CLMT) at $36.16 ($0.15M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sajkowski Daniel J
Published Jul 2, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

The disclosure confirms an open-market sale by a director executed under a pre-arranged 10b5-1 plan; it does not provide new operating, financial, or regulatory information.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to drive price without additional company-specific catalysts.

03

What to watch

Insider sales are common and often tax/portfolio-driven; without context on total insider activity or concurrent company news, signal quality is low.

Relevance 3/10Novelty 5/10Timing: Filed 2026-07-02; sale executed 2026-07-01.

Background

SEC Form 4 reports an insider transaction for Calumet, Inc. (CLMT).

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet, Inc. insider Daniel J. Sajkowski sold 4,240 shares on 2026-07-01 under a pre-arranged 10b5-1 plan for ~$153.3K.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 sale (not a buy), but it specifies a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

None—single-company insider transaction with no sector-wide datapoint.

None.

None.

Counterpoint

A 10b5-1 sale can still coincide with insider expectations of near-term risk, but the plan structure usually limits the informational edge.

Key entities

  • Calumet, Inc.

    Subject of the Form 4 insider transaction; ticker CLMT.

  • Daniel J. Sajkowski

    Director who sold 4,240 shares on 2026-07-01 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLMTMed

Calumet stock hits 52-week high at 54.72 USD

Calumet Specialty Products Partners (CLMT) hit a 52-week high of $54.72, up 205.27% over the past year. The company reported Q2 2026 revenue of $1.44B, beating estimates, but missed earnings expectations. S&P upgraded its credit rating to 'B-', while UBS and TD Cowen raised price targets to $47 and $40, respectively, with Neutral/Hold ratings.

$CLMTMed

Q2 Earnings Highlights: Calumet (NASDAQ:CLMT) Vs The Rest Of The Infrastructure Stocks

Calumet (CLMT) stock rose 8.9% post-earnings, trading at $16.19. Kodiak Gas Services (KGS) reported $391.1M revenue, up 21.1% YoY, with stock up 10.5% to $62.81. Excelerate Energy (EE) saw $329.3M revenue, up 61% YoY, with stock up 3% to $39.65. DHT Holdings (DHT) reported $255.2M revenue, up 174% YoY, with stock up 13% to $20.19. Market focus has shifted from AI to geopolitics and back to fundamentals.

$CLMTMed

Why Calumet Stock Topped the Market Today

Calumet (CLMT) stock rose 3% after the EPA granted full exemptions for two refineries, removing 71 million RINs from its balance sheet. The company values remaining RINs at $309 million. Calumet is also seeking exemptions for 2022-2024, which are under review. The exemptions improve its financials by reducing compliance costs.